License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Affiliations
Yvette H. van Beurden
Dept. of Gastroenterology & Hepatology ; Dept. of Medical Microbiology & Infection Control, VU University Medical Center, Amsterdam, The Netherlands
Tom van Gils
Dept. of Gastroenterology & Hepatology, VU University Medical Center, Amsterdam, The Netherlands
Nienke A. van Gils
Dept. of Gastroenterology & Hepatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands
Zain Kassam
Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; OpenBiome, Medford, Massachusetts, USA.
Chris J.J. Mulder
Dept. of Gastroenterology & Hepatology, VU University Medical Center, Amsterdam, The Netherlands
Nieves Aparicio-Pagés
Dept. of Gastroenterology & Hepatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands
How to Cite
Serendipity in Refractory Celiac Disease: Full Recovery of Duodenal Villi and Clinical Symptoms after Fecal Microbiota Transfer
Abstract
Treatment of refractory celiac disease type II (RCD II) and preventing the development of an enteropathy associated T-cell lymphoma in these patients is still difficult. In this case report, we describe a patient with RCD II who received fecal microbiota transfer as treatment for a recurrent Clostridium difficile infection, and remarkably showed a full recovery of duodenal villi and disappearance of celiac symptoms. This case suggests that altering the gut microbiota may hold promise in improving the clinical and histological consequences of celiac disease and/or RCD II.
Abbreviations: CDI: Clostridium difficile infection; EATL : enteropathy associated T-cell lymphoma; FMT: fecal microbiota transfer; IEL: intraepithelial lymphocytes; RCD II: refractory celiac disease type II; TPN: total parenteral nutrition.